Abeona Therapeutics (ABEO) Income from Non-Controlling Interests (2020 - 2026)
Abeona Therapeutics' (ABEO) quarterly Income from Non-Controlling Interests came in at -$159000.0 in Q1 2026, down 112.0% year-on-year from $1.3 million in Q1 2025, and down 224.22% quarter-over-quarter from $128000.0 in Q4 2025.
Abeona Therapeutics (ABEO) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Abeona Therapeutics' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$159000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 112.0% year-over-year to -$159000.0 in Q1 2026; TTM through Mar 2026 was $46000.0, a 60.68% decrease from a year earlier, with the FY2025 full-year figure at $130000.0, up 75.68% from the prior year.
- Income from Non-Controlling Interests declined to -$159000.0 in Q1 2026 per ABEO's latest filing, from $128000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $128000.0 in Q4 2025 and bottomed at -$159000.0 in Q1 2026.
- The 5-year median for Income from Non-Controlling Interests is -$3000.0 (2022), against an average of -$1176.5.
- Across the five-year window, Income from Non-Controlling Interests slumped 8700.0% in 2022 and soared 2233.33% in 2023, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$88000.0 in 2022, then surged by 137.5% to $33000.0 in 2023, then jumped by 178.79% to $92000.0 in 2024, then surged by 39.13% to $128000.0 in 2025, then tumbled by 224.22% to -$159000.0 in 2026.
- Per Business Quant, the three latest ABEO Income from Non-Controlling Interests figures stand at -$159000.0 (Q1 2026), $128000.0 (Q4 2025), and $55000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Abeona Therapeutics | 107.85 Mn | -60.42 Mn | 6.02 Mn | -159,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -159,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | -75,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | -118,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | -33,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | 64,000.00 |
| Dec 31, 2022 | -88,000.00 |
| Sep 30, 2022 | -4,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -4,000.00 |